Pharmosa Biopharm (ROCO:6875) Loans Receivable: NT$0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6875 Pharmosa Biopharm Inc ROCO:6875
27 GF Score
Price NT$33.00
GF Value NT$15.32
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Pharmosa Biopharm Loans Receivable?

Pharmosa Biopharm ROCO:6875 27 Loans Receivable is NT$0.00 Mil as of Jun. 2026. GuruFocus rates ROCO:6875 with a GF Score™ of 27/100 and a GF Value™ of NT$15.32 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Pharmosa Biopharm's Loans Receivable for the quarter that ended in Jun. 2026 was NT$0.00 Mil.

Pharmosa Biopharm Loans Receivable Related Terms

Pharmosa Biopharm Loans Receivable Historical Data

* Premium members only.

The historical data trend for Pharmosa Biopharm's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmosa Biopharm Loans Receivable Chart

Pharmosa Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Pharmosa Biopharm Quarterly Data
Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:6875
27GF Score
Pharmosa Biopharm Inc ROCO:6875
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmosa Biopharm Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of NT$0.00 Mil mean?
Pharmosa Biopharm (ROCO:6875) has a Loans Receivable of NT$0.00 Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Pharmosa Biopharm and its competitors.
Is Pharmosa Biopharm's Loans Receivable too high?
Pharmosa Biopharm's current Loans Receivable is NT$0.00 Mil. Overall, Pharmosa Biopharm has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmosa Biopharm's Loans Receivable compare to VRTX and REGN?
Pharmosa Biopharm's Loans Receivable of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Pharmosa Biopharm and its competitors. Pharmosa Biopharm's current Loans Receivable is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmosa Biopharm stock overvalued right now?
Based on GuruFocus' analysis, Pharmosa Biopharm (ROCO:6875) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$15.32, compared to a current price of NT$33.00 — trading 115.4% above its estimated fair value. The current Loans Receivable is NT$0.00 Mil. Pharmosa Biopharm's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Pharmosa Biopharm (ROCO:6875), the current Loans Receivable is NT$0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmosa Biopharm (ROCO:6875) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmosa Biopharm stock appears to be overvalued. The current stock price of NT$33.00 is trading 115.4% above its estimated GF Value™ of NT$15.32. GuruFocus considers Pharmosa Biopharm to be Significantly Overvalued.

Key valuation signals for ROCO:6875:

  • Loans Receivable: NT$0.00 Mil
  • GF Value™: NT$15.32 vs. price of NT$33.00 (115.4% above fair value)
  • GF Score™: 27/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6875 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmosa Biopharm Business Description

Address No. 508, Sec. 7, Zhongxiao E. Road, 11th Floor / 11th Floor-1, Nangang District, Taipei, TWN
Pharmosa Biopharm Inc is a world-class biotechnology company. The Company's principal business activities comprise the development and commercialization of inventive biopharmaceutical drugs. Its product portfolio includes sustained-release dosage forms and drug-device combination products intended for home based therapies.
27GF Score

Get the complete analysis for ROCO:6875

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$33.00
Price
NT$15.32
GF Value